Evaluation of Colitis Model Establishment with Different DSS Concentrations

Dextran sulfate sodium (DSS)-induced colitis is one of the most widely used animal models for studying inflammatory bowel disease, and the concentration of DSS administered directly determines the severity, reproducibility, and survival rate of the model. This article provides a systematic evaluation of model establishment effects across different DSS concentrations, covering experimental design, evaluation parameters, histopathological findings, and practical guidance for protocol optimization.

Technical Overview

Dextran sulfate sodium (DSS) is a sulfated polysaccharide that, when administered in drinking water to laboratory mice, disrupts the intestinal epithelial barrier and triggers acute or chronic colitis that closely resembles human inflammatory bowel disease (IBD). The concentration of DSS is the single most critical variable governing model outcome: insufficient concentrations produce mild, inconsistent inflammation, whereas excessive concentrations cause excessive weight loss, high mortality, and uninterpretable data. A systematic evaluation of different DSS concentrations is therefore essential before initiating any pharmacological intervention study.

Model establishment effects are typically evaluated using a combination of clinical indicators (body weight change, disease activity index, fecal characteristics), macroscopic endpoints (colon length, colon weight-to-length ratio), histopathological scoring of H&E-stained colon sections, and molecular biomarkers of inflammation. The optimal DSS concentration must balance disease severity against animal welfare and experimental reproducibility, and it varies with mouse strain, age, sex, DSS molecular weight, and study duration.

Testing Samples

Animal Subjects

Concentration evaluation studies are commonly performed using specific pathogen-free (SPF) mice, as the following factors significantly influence DSS sensitivity:

• C57BL/6 mice: high sensitivity to DSS, the most frequently used strain for concentration-response studies
• BALB/c mice: moderate sensitivity, often requiring higher DSS concentrations to achieve comparable disease severity
• Mice aged 6–10 weeks with body weights of 18–25 g, maintained under standardized housing, diet, and environmental conditions
• Both male and female cohorts may be evaluated separately, as sex-related differences in DSS susceptibility have been reported

DSS Reagents

The physicochemical properties of the DSS reagent itself affect model outcomes and must be controlled during evaluation:

• DSS molecular weight: 36,000–50,000 Da is the standard range for colitis induction; reagents of 5,000 Da or 500,000 Da produce weaker or atypical responses
• Sulfur content: typically 16–20%, with higher degrees of sulfation generally increasing colitogenic potency
• Reagent grade: colitis-grade DSS (such as reagents qualified for murine colitis induction) is strongly recommended over general-purpose DSS
• Freshly prepared DSS solutions in sterile drinking water, protected from light and replaced every 2–3 days to ensure stable effective concentration

Testing Items

A comprehensive evaluation of model establishment effects across different DSS concentrations incorporates the following testing items:

• Body weight monitoring: daily measurement, with significant weight loss expressed as percentage change from baseline
• Disease Activity Index (DAI): a composite score of weight loss, stool consistency, and fecal occult blood or gross bleeding, each scored 0–4
• Colon length measurement: shortening of the colon is a robust macroscopic marker of inflammation severity
• Colon weight-to-length ratio: an indicator of edema and tissue inflammation
• Histopathological examination: H&E-stained distal colon sections scored for epithelial damage, crypt loss, and inflammatory cell infiltration
• Myeloperoxidase (MPO) activity: quantifies neutrophil infiltration in colonic tissue
• Inflammatory cytokines: TNF-α, IL-6, IL-1β, IL-10, and IL-17 levels in colon tissue or serum measured by ELISA or multiplex assays
• Intestinal barrier markers: fecal lipocalin-2, serum LPS, tight junction protein expression (ZO-1, occludin, claudins)
• Survival rate and humane endpoint monitoring throughout the induction period

Testing Methods

Experimental Design

Mice are randomized into groups receiving different DSS concentrations in drinking water ad libitum for a defined induction period. A typical concentration evaluation scheme for acute colitis includes:

• Control group: normal drinking water without DSS
• Low-concentration group: 1.0–1.5% DSS (w/v)
• Medium-concentration group: 2.0–3.0% DSS (w/v)
• High-concentration group: 4.0–5.0% DSS (w/v)
• Induction period: 5–7 days for acute colitis, with a recovery observation phase of 2–3 days in some protocols

Clinical Observation and Scoring

Body weight, stool consistency, and signs of gross bleeding are recorded daily by blinded observers. The DAI is calculated as the mean of the three subscores. Weight loss is scored as 0 (none), 1 (1–5%), 2 (5–10%), 3 (10–20%), and 4 (>20%). Fecal blood is assessed using guaiac-based or immunochemical occult blood tests. Animals exceeding humane endpoints (typically >20% body weight loss or severe morbidity) are removed from the study and euthanized.

Tissue Collection and Analysis

At the end of the induction period, animals are euthanized and the entire colon is excised from cecum to anus. Colon length is measured under consistent tension, and the organ is opened longitudinally for gross lesion scoring. Distal colon segments are fixed in 4% paraformaldehyde, paraffin-embedded, sectioned, and stained with H&E for blinded histological scoring. Remaining tissue is snap-frozen for MPO assays, cytokine quantification, and Western blot or qPCR analysis of barrier and signaling proteins.

Expected Concentration-Response Outcomes

The characteristic model establishment profile observed across DSS concentrations is summarized below:

• 1–1.5% DSS: mild colitis with minimal weight loss (<5%), slight DAI elevation, preserved colon length, and mild histological changes; suitable for chronic cycling protocols but often insufficient for acute drug efficacy screening
• 2% DSS: moderate, highly reproducible colitis with 5–10% weight loss, elevated DAI (3–6), measurable colon shortening, crypt damage, and moderate inflammatory infiltration; frequently identified as the optimal concentration for C57BL/6 acute models
• 3% DSS: pronounced colitis with 10–15% weight loss, high DAI (6–8), marked colon shortening, extensive epithelial ulceration, and strong cytokine elevation; suitable for evaluating therapeutic agents expected to provide substantial protection
• 4–5% DSS: severe fulminant colitis with rapid weight loss exceeding 20%, high mortality (often 20–50%), and extensive transmural inflammation; useful for studying epithelial repair mechanisms but frequently too severe for intervention studies

Chronic colitis models typically employ 2–3% DSS administered in repeated cycles (for example, 5 days of DSS followed by 10–14 days of normal water, repeated three or more times), allowing evaluation of fibrosis, dysplasia, and long-term immune remodeling.

Applications

Evaluation of model establishment effects at different DSS concentrations supports a wide range of research and development applications:

• Preclinical efficacy screening of anti-inflammatory drugs, biologics, and small molecules for IBD therapy
• Mechanistic studies of epithelial barrier function, innate immunity, and the gut microbiome–intestinal inflammation axis
• Selection and validation of the optimal induction concentration for a specific strain, facility, or therapeutic window prior to formal pharmacology studies
• Evaluation of protective compounds such as probiotics, dietary fibers, natural products, and functional food ingredients
• Establishment of chronic fibrosis and colitis-associated carcinogenesis models when combined with repeated DSS cycles and carcinogens
• Biomarker discovery and translational research bridging murine colitis with ulcerative colitis and Crohn's disease in humans

FAQ

Which DSS concentration is most commonly used for acute colitis in C57BL/6 mice?

A concentration of 2–3% DSS (36–50 kDa) administered for 5–7 days is most commonly used for C57BL/6 mice, as it reliably induces moderate-to-severe acute colitis while maintaining acceptable survival rates. The exact optimum should be validated in each facility because DSS lot potency and husbandry conditions influence outcomes.

Why do different mouse strains require different DSS concentrations?

Strain-dependent differences in epithelial barrier integrity, immune responsiveness, and microbiota composition lead to different sensitivities. C57BL/6 mice are highly sensitive, whereas BALB/c and 129 strains often require higher concentrations or longer exposure to achieve comparable disease scores. Running a pilot concentration evaluation is recommended whenever a new strain is introduced.

How is the success of DSS model establishment determined?

A model is considered successfully established when mice exhibit significant weight loss, elevated DAI scores (typically ≥3), obvious colon shortening compared with controls, and histological evidence of epithelial damage and inflammatory infiltration, accompanied by increased inflammatory cytokines and MPO activity. Statistically significant differences from the control group across multiple endpoints confirm successful induction.

What should be done if 2% DSS produces inconsistent results?

Inconsistency is commonly resolved by verifying the DSS molecular weight and lot quality, ensuring fresh solution preparation every 2–3 days, confirming individual water consumption is comparable across cages, standardizing cage density and environmental conditions, and, if necessary, adjusting the concentration by 0.5% increments in a small pilot cohort.

Can the same DSS concentration be reused for chronic colitis studies?

Yes, but chronic models generally use a slightly lower concentration (typically 2%) delivered in repeated induction-recovery cycles rather than a single continuous exposure. This design produces sustained inflammation, fibrosis, and immune adaptation while avoiding the excessive mortality associated with prolonged high-dose DSS exposure.